# A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Source: https://onco.cc/trials/nct07336446/  
OnCo record `nct07336446` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is active not recruiting.

## Summary

The registry lists NCT07336446 as active not recruiting, last updated 2026-10-02. Enrolment is 6 actual participants. Interventions: AZD9750, AZD5305. Primary measures include Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only); Number of participants with Adverse Events and Serious Adverse Events. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Also known as: ANDROMEDA
- Tags: ctgov-ingest
- Registry id: NCT07336446
- Phase: 1/2
- Setting: A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)
- Sponsor: AstraZeneca
- Enrolled: 6

## Sources

- ClinicalTrials.gov NCT07336446: https://clinicaltrials.gov/study/NCT07336446

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [AZD9750](https://onco.cc/drugs/azd9750/), [Saruparib](https://onco.cc/drugs/saruparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07336446.json